Back

Interrupted vs uninterrupted direct oral anticoagulants compared with uninterrupted vitamin K antagonists for atrial fibrillation ablation - A meta-analysis of safety

31 March 2025 (08:25 - 09:15)
Organised by: Logo
Congress Presentation Part of: Atrial fibrillation catheter ablation complications (1) Rhythm Control, Catheter Ablation EHRA Premium Access EHRA 2025 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Dan Musat

The Valley Hospital, Paramus (United States of America)

5 More presentations in this session

Presentation thumbnail
A novel method for phrenic nerve monitoring during cryo-balloon procedures
Doctor A. Marinelli (Palermo, IT)
Abstract Slides Video
Presentation thumbnail
Safety and efficacy of a nurse-led deep sedation protocol for invasive pulsed-field ablation of atrial fibrillation
Doctor D. Rodriguez Munoz (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
Analysis of hemolysis following pulse field ablation using three different technologies
Doctor L. Marcon (Brussels, BE)
Abstract Slides Video
Presentation thumbnail
Left atrium size and the risk of atrio-esophageal fistula following thermal ablation in patients with atrial fibrillation
Doctor A. Natale (Austin, US)
Abstract Slides Video
Presentation thumbnail
Cerebral safety of two different pulsed field ablation systems for pulmonary vein isolation: the TWOSOME MRI substudy
Doctor S. Hartl (Essen, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Atrial fibrillation catheter ablation complications (1)

The Event

Event poster

EHRA 2025

31 March 2025 08:25 CET
You may be interested in
thumbnail
Congress Presentation
Anticoagulation strategy of choice for atrial fibrillation ablation - a network meta-analysis of complication rates
thumbnail
Congress Presentation
Interrupted or uninterrupted direct oral anticoagulants for atrial aibrillation ablation which is the best strategy insights from a network meta-analysis
thumbnail
Congress Presentation
Uninterrupted trumps interrupted vitamin k antagonists as peri-atrial fibrillation ablation strategy - a network meta-analysis of safety in more than 25000 patients

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources